Q-omics provides the consensus-scored C2orf92 profile across patient tissues and cancer cell-line models. C2orf92 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C2orf92 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C2orf92 RNA expression shows 19,910 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where C2orf92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf92 survival associations across molecular data types. C2orf92 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf92 RNA expression–survival associations across cancer types. High C2orf92 expression shows unfavorable associations in ACC, KIRC, LGG and DLBC, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for C2orf92 RNA expression.
This table summarizes C2orf92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C2orf92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf92 shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in KIRC, LIHC and COAD. The KIRC box plot shows higher C2orf92 RNA expression in tumor versus normal tissue (log2 FC = +0.311, t-test p < 0.001).
This table shows molecular features associated with C2orf92 in patient tissues and cancer cell lines. In patient samples, C2orf92 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
